← Back to Search

Alpha V Beta 6 Integrin Inhibitor

PLN-74809 Dose Level 2 (80 mg) for Idiopathic Pulmonary Fibrosis (IPF-201 Trial)

Phase 2
Waitlist Available
Research Sponsored by Pliant Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up following 1 day of administration of pln-74809
Awards & highlights

IPF-201 Trial Summary

This trial is testing if a new drug can help treat mild to moderate IPF by targeting a protein called αVβ6.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

IPF-201 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~following 1 day of administration of pln-74809
This trial's timeline: 3 weeks for screening, Varies for treatment, and following 1 day of administration of pln-74809 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With a Predicted Effect on αVβ6 PET ( Positron Emission Tomography) in Lungs After Administration of Drug.
Secondary outcome measures
Safety and Tolerability of PLN-74809 as Measured by the Number / Percentage of Adverse Events
Other outcome measures
Relationship between PLN-74809 systemic exposure, αvβ6 receptor occupancy and biomarkers in IPF participants

IPF-201 Trial Design

5Treatment groups
Experimental Treatment
Group I: PLN-74809 Dose Level 4 (320 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 4 (320 mg)
Group II: PLN-74809 Dose Level 4 (240 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 4 (240 mg)
Group III: PLN-74809 Dose Level 3 (120 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 3 (120 mg)
Group IV: PLN-74809 Dose Level 2 (80 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 2 (80 mg)
Group V: PLN-74809 Dose Level 1 (60 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 1 (60mg)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Knottin tracer
2020
Completed Phase 2
~10
PLN-74809
2020
Completed Phase 2
~260

Find a Location

Who is running the clinical trial?

Stanford UniversityOTHER
2,408 Previous Clinical Trials
17,343,430 Total Patients Enrolled
4 Trials studying Idiopathic Pulmonary Fibrosis
90 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
724 Total Patients Enrolled
4 Trials studying Idiopathic Pulmonary Fibrosis
520 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Pliant Therapeutics Medical MonitorStudy DirectorPliant Therapeutics, Inc.
4 Previous Clinical Trials
678 Total Patients Enrolled
2 Trials studying Idiopathic Pulmonary Fibrosis
480 Patients Enrolled for Idiopathic Pulmonary Fibrosis
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top